Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
59.38
+0.17 (0.29%)
At close: Jun 12, 2026, 4:00 PM EDT
60.18
+0.80 (1.35%)
After-hours: Jun 12, 2026, 6:35 PM EDT

Nektar Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Nektar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $153.25. The average 1-year stock price forecast is 158.08% higher than the current stock price, while the lowest is $80 (+34.73%) and the highest is $192 (+223.34%).

Price Target: $153.25 (+158.08%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$80$153.25$150.5$192
Change+34.73%+158.08%+153.45%+223.34%
* Price targets were last updated on May 14, 2026.

Analyst Ratings

The average analyst rating for Nektar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy667888
Buy111111
Hold110111
Sell000000
Strong Sell000000
Total888101010

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Citi
Citi
Buy
Maintains
$76$151
BuyMaintains$76$151+154.29%May 14, 2026
Wedbush
Wedbush
Hold
Maintains
$95$80
HoldMaintains$95$80+34.73%May 11, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$185
BuyMaintains$185+211.55%May 11, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$140
BuyMaintains$140+135.77%May 8, 2026
BTIG
BTIG
Buy
Maintains
$178
BuyMaintains$178+199.76%May 8, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
41.22M
from 55.23M
Decreased by -25.37%
Revenue Next Year
36.91M
from 41.22M
Decreased by -10.46%
EPS This Year
-9.54
from -8.66
EPS Next Year
-12.56
from -9.54
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
101.91M92.06M90.12M98.43M55.23M41.22M
Revenue Growth
-33.36%-9.67%-2.10%9.22%-43.89%-25.37%
Gross Profit
77.01M70.42M56.35M67.74M55.23M41.22M
Gross Margin
75.57%76.50%62.53%68.82%100.00%100.00%
Operating Income
-446.10M-240.24M-135.23M-129.92M-130.77M-233.24M
Net Income
-523.84M-368.20M-276.06M-118.96M-164.08M-250.03M
EPS
-----8.66-9.54
Free Cash Flow
-234.18M-101.13M-63.63M-43.69M-108.23M-185.95M
No. Analysts
-----10
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High44.8M
Avg41.2M
Low24.0M

Revenue Growth

Revenue Growth202620272028
High
-19.0%
Avg
-25.4%
Low
-56.5%

EPS Forecast

EPS202620272028
High-
Avg-9.54
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-